| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.9 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.0091 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.0056 | 0.9 |